NASDAQ:INVA Innoviva Q4 2024 Earnings Report $21.89 -0.24 (-1.08%) Closing price 04:00 PM EasternExtended Trading$21.89 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innoviva EPS ResultsActual EPS$0.57Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInnoviva Revenue ResultsActual Revenue$91.81 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInnoviva Announcement DetailsQuarterQ4 2024Date2/26/2025TimeAfter Market ClosesConference Call DateWednesday, February 26, 2025Conference Call Time4:00PM ETUpcoming EarningsInnoviva's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, July 30, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Innoviva Earnings HeadlinesTheravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19May 27 at 8:50 PM | tipranks.comInnoviva (NASDAQ:INVA) Lowered to "Hold" Rating by Wall Street ZenMay 17, 2026 | americanbankingnews.comSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, metals, textiles, and industrial commodities to give physical materials a digital identity. Its Digital Material Passport technology targets verification of origin, recycled content, and lifecycle data across global supply chains - a market growing more compliance-driven by the day. As governments tighten recycled-content reporting standards, SMX is positioning itself inside one of the decade's most consequential industrial shifts.May 28 at 1:00 AM | Smallcaps Daily (Ad)Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?May 11, 2026 | finance.yahoo.comInnoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty StrengthMay 8, 2026 | insidermonkey.comInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressMay 6, 2026 | businesswire.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma. The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches. Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake and the Snowballing Impact of its AI FlywheelThis Quantum Computing Stock May Be Closer to a Breakout Than You ThinkMicrosoft Is Spending Billions on AI, But Investors Aren’t Buying ItSemtech’s Explosive Rally May Only Be Getting StartedBath & Body Works Stock Surged Despite Falling Sales—Here’s WhyAbercrombie Rallies as Strong Q1 Earnings Extend Winning StreakDick’s Sporting Goods Isn’t Done Winning Yet Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
